Israel - English - Ministry of Health

abic ltd. - omeprazole - capsules - omeprazole 20 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. reflux esophagitis:- treatment ; - long-term management; - maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. treatment of severe reflux oesophagitis in children from one year of age and older. - maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - zollinger-ellison syndrome. - treatment and prevention of nsaid - associated duodenal and gastric ulcers or erosions in high risk patients.

Israel - English - Ministry of Health

abic ltd. - omeprazole - capsules - omeprazole 20 mg - omeprazole - omeprazole - relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - omeprazole - capsules - omeprazole 20 mg - omeprazole - relief of reflux-like symptoms (e.g. heartburn) with frequency of two or more days a week in sufferers aged 18 and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - omeprazole magnesium, quantity: 20.6 mg (equivalent: omeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: titanium dioxide; hypromellose; triethyl citrate; crospovidone; hyprolose; purified talc; macrogol 6000; methacrylic acid copolymer; iron oxide red; magnesium stearate; glyceryl monostearate; polysorbate 80; sodium stearylfumarate; microcrystalline cellulose; sodium hydroxide; synthetic paraffin; maize starch; sucrose - gastro-oesophageal reflux disease (gord). 1. symptomatic gord. the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis. the treatment and prevention of relapse. peptic ulcers. 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infections. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. zollinger-ellison syndrome. the treatment of zollinger-ellison syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - omeprazole magnesium, quantity: 10.3 mg (equivalent: omeprazole, qty 10 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; glyceryl monostearate; titanium dioxide; hyprolose; purified talc; iron oxide yellow; macrogol 6000; sodium stearylfumarate; iron oxide red; methacrylic acid copolymer; triethyl citrate; polysorbate 80; hypromellose; magnesium stearate; crospovidone; sodium hydroxide; synthetic paraffin; maize starch; sucrose - gastro-oesophageal reflux disease (gord). 1. symptomatic gord. the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis. the treatment and prevention of relapse. peptic ulcers. 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infections. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be helicobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. zollinger-ellison syndrome. the treatment of zollinger-ellison syndrome.

Israel - English - Ministry of Health

abic ltd. - omeprazole - capsules - omeprazole 20 mg - omeprazole - acute duodenal ulcer. acute gastric ulcer. helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. reflux esophagitis:- treatment ; - long-term management; - maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. treatment of severe reflux oesophagitis in children from one year of age and older. - maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - zollinger-ellison syndrome. - treatment and prevention of nsaid - associated duodenal and gastric ulcers or erosions in high risk patients.

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - omeprazole magnesium (unii: 426qfe7xlk) (omeprazole - unii:kg60484qx9) - omeprazole 10 mg - prilosec is indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy prilosec in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy prilosec in combination with clarithromycin is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, prilosec with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, susceptibility testing should be done. if resistance to clarithromycin is demonstrated or susceptibility testing is not pos

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - omeprazole magnesium -

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole;   - enteric coated tablet - 10 mg - active: omeprazole magnesium 10.3mg equivalent to 10 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) hydroxypropylcellulose iron oxide yellow macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres synthetic paraffin titanium dioxide triethyl citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole;   - enteric coated tablet - 20 mg - active: omeprazole magnesium 20.6mg equivalent to 20 mg omeprazole   excipient: crospovidone ferrous oxide glyceryl monostearate hard paraffin hyprolose hypromellose methacrylic acid-ethyl acrylate copolymer (1:1) macrogol 6000 magnesium stearate microcrystalline cellulose polysorbate 80 purified talc sodium hydroxide sodium stearyl fumarate sugar spheres titanium dioxide triethyl citrate - the short-term relief of reflux-like symptoms in patients aged 18 years and over.